SlideShare a Scribd company logo
Analyzing Aggregates by Sedimentation
Velocity and Light Scattering
John Philo
Director of Biophysical Chemistry
© copyright 2006, Alliance Protein Laboratories, Inc.
Images or text may not be reproduced without permission.
Outline
Quickly review some basic facts about
aggregate sizes and types
Basic principles and application examples
for 3 methods
1. sedimentation velocity
2. classical light scattering used with SEC
3. batch-mode dynamic light scattering
The word “aggregate” covers a wide spectrum
of types and sizes of associated states
1. rapidly-reversible non-covalent small
oligomers (dimer, trimer, tetramer…)
2. irreversible non-covalent oligomers
3. covalent oligomers (e.g. disulfides)
4. “large” aggregates (> 10-mer)
could be reversible if non-covalent
5. “very large” aggregates (diameter ~50 nm
to 3 μm)
could be reversible if non-covalent
6. visible particulates
probably irreversible
Aggregates have a spectrum of lifetimes
rates of non-covalent association and dissociation (half-
times) can vary from milliseconds to days
metastable oligomers with dissociation rates of hours to
days occur fairly frequently
for an antibody example see J.M.R. Moore et al. (1999)
Biochemistry 38: 13960-13967
see also Philo, J.S. (2006) AAPS Journal, in press
many common analytical methods will detect only the
longer-lived species
it may take hours to days for a protein to re-equilibrate
its association after a change in concentration, solvent
conditions or temperature
Our analytical challenge
1. Any protein sample may contain aggregates
with a wide range of sizes, types, and lifetimes
2. Any one analysis method may not detect all
the aggregate sizes or types that are present
3. The measurement itself may perturb the
aggregate distribution that was initially present
dilution may dissociate reversible aggregates
change of solvent conditions may dissociate or increase
aggregates
adsorption or filtration effects may remove aggregates
Sedimentation velocity
The fundamentals of sedimentation velocity
6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0
Radius (cm)
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5
Absorbance
6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0
Radius (cm)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Absorbance
centrifugal
force
diffusion
← meniscus
The sedimentation coefficient
is determined from the
boundary motion over time. It
depends on both molecular
weight and molecular shape.
cell base →
friction
←regionofsolute
depletion
boundary
High resolution analysis of a highly stressed antibody
sample resolves 6 aggregate peaks plus 2 fragments
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.2
0.4
0.6
0.8
1.0
heptamer,0.1%
hexamer,0.4%
pentamer1.4%
tetramer5.3%
trimer14.6%
dimer30.6%
main peak (monomer), 45.5%
?HLhalfmolecule,0.8%
?freelightchain,1.4%
c(s),normalized(totalarea=1)
sedimentation coefficient (Svedbergs)
The peril: c(s) distributions are also often
misunderstood
1. the effective resolution goes down as the fraction of
minor peaks goes down
2. the resolution you can achieve for a 150 kDa antibody
is much greater than for a 20 kDa cytokine
3. in general it is not possible to uniquely assign a
stoichiometry to each aggregate peak
4. the nature of the noise (variability) is very different
than in chromatography
5. for reversibly associating proteins the peaks probably
do not represent individual molecular species
This interferon-β sample is 13.7% non-covalent aggregate;
by the standard SEC method it would be pure monomer
0 2 4 6 8 10
0
1
2
3
4
5
6
7
0 2 4 6 8 10
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
IFN-β in 5 mM glycine, pH 3, 86.3% main peak
c(s)
sedimentation coefficient (Svedbergs)
0
1
2
3
0.0
0.5
1.0
1.5
0 8 16 24 32 40
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
no salt
c(s)
+50 mM NaCl
c(s)
+150 mM NaCl
c(s)
sedimentation coefficient (Svedbergs)
0 2 4 6 8 10
0.00
0.05
0.10
0.15
20X expanded
0 2 4 6 8 10
0.00
0.05
0.10
0.15
20X expanded
Adding NaCl to interferon-β formulations leads to a broad
distribution of non-covalent aggregates out to ~100-mers
Strengths of sedimentation velocity
1. high resolution (often better than SEC)
2. covers very large range of masses in a single
experiment (much larger than SEC)
3. detects both covalent and non-covalent aggregates
4. generally can be done directly in formulation buffers
Tween and high levels of sugars do cause some
interference
5. little dilution of sample (~25%)
6. absolute method; requires no molecular standards
7. strong theoretical background; “first principles”
method
Weaknesses of sedimentation velocity
1. low throughput (3-7 samples/day)
2. equipment and data analysis not automated like
HPLC; labor intensive
3. expensive equipment (~250-300 K$)
4. requires substantial training
5. never been validated for lot release
Sedimentation velocity can not replace SEC, but it
is an excellent tool to test whether SEC is missing
important features. It can also serve as a “gold
standard” to help improve SEC methods.
Multi-angle classical laser light
scattering used on-line with SEC
(SEC-MALLS)
Typical setup for size-exclusion chromatography
with on-line light scattering detection
light scattering
detector
absorbance
detector
refractive index
detector
size-exclusion
column
injectorpumpsolvent
Getting molecular mass from static light
scattering: the basic idea
the light scattering signal is proportional to the
product c × M
we measure c simultaneously with a UV or RI
detector
then the ratio of the scattering to concentration
signals will be proportional to M
masses obtained this way are absolute, and
independent of conformation and elution position
Demonstrating that scattering is independent of elution position
and molecular conformation: the ratio of LS to RI signals is the
same whether the protein is folded or unfolded
18 20 22 24 26 28
signal(arbitraryunits)
LS
RI
LS
RI
Native
RNase
Unfolded (reduced &
carboxymethlyated)
RNase
Retention Time (min)
An example for an Fc-fusion protein: the aggregate signals are
much stronger in 90° scattering than in the UV chromatogram
scattering intensity RI
elution volume (ml)
5.0 6.0 7.0 8.0 9.0 10.0 11.0
relativescale
0.0
0.2
0.4
0.6
0.8
1.0
“Oligomer hunting”: display the absolute molecular
weight from LS in units of monomers
6 7 8 9 10 11
0
1
2
3
4
5
6
7
8
9
10
massratiorelativetomainpeak
elution volum e (m l)
This antibody sample has traces of dimer and trimer
12 13 14 15 16 17 18
Elution Volume (ml)
0.0
1.0
2.0
3.0
4.0
5.0
relativemassfromLS/UV
relative mass (LS/UV) UV (arb units)
A different lot contains more higher oligomers, and they
are so sticky that even dimer is no longer resolved
11 12 13 14 15 16 17 18
Elution Volume (ml)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
relativemassfromLS/UV
relative mass (LS/UV) UV (arb units)
volume (ml)
5.0 6.0 7.0 8.0 9.0 10.0
relativescale
0.0
0.2
0.4
0.6
0.8
1.0
This highly stressed sample of a VaxGen test antigen
showed high levels of an SEC peak eluting near the
position expected for a dimer
monomer
dimer?
large
aggregates
However SEC-MALLS immediately shows that alleged
aggregate is actually an altered form of monomer!
molar mass vs. volume
volume
5.0 6.0 7.0 8.0 9.0 10.0
molarmass(g/mol)
5
1.0x10
6
1.0x10
7
1.0x10
Strengths of SEC + classical LS
1. absolute molecular mass, independent of
conformation or elution position
2. gives us at least an average mass for the
“aggregate” fraction near the exclusion limit
3. helps tell us whether our chromatography is really
working properly
4. high throughput, low cost (comparable to the HPLC
it is used with), fairly easy
5. absolute method; requires no molecular standards
6. strong theoretical background; “first principles”
method
Weaknesses of SEC + classical LS
1. it inherits all the problems of SEC (change in
aggregate distribution from dilution, change in buffer,
adsorption/filtration, etc.)
2. while it is very sensitive to high MW aggregates,
quantitation of % by weight still relies on the
concentration detector (RI or UV)
3. particles shed from columns may obscure the elution
region near the column’s exclusion limit
4. good signal/noise may require larger injection amounts
than are normally used in standard SEC
Batch-mode dynamic light scattering
(DLS)
also known as quasi-elastic light
scattering (QELS) or photon
correlation spectroscopy (PCS)
One particularly vexing type of aggregation is “snow”
(a.k.a. “white amorphous material” [WAM] or “floaters”)
• may only appear after many months
• often a nucleation-controlled reaction
• often ≤ 0.01% of total protein
⇒
When this happens our valuable therapeutic
protein can only be used for…
Dynamic scattering is one of the few tools that may be
able to detect the precursors that eventually form ‘snow’
Dynamic light scattering: the basic idea
1. In dynamic scattering we measure the
fluctuations in scattering intensity (~100 ns to
30 ms)
2. The time scale of those fluctuations depends
on the diffusion coefficient of the
macromolecule, which in turn depends on its
size
3. As in classical LS, the scattering intensity is
proportional to M, so the sensitivity to very
large aggregates is very high
Typically the data are transformed into a distribution of
hydrodynamic radius; this distribution shows 3 peaks
2.16 nm, 79.0% of intensity
92.3 nm,
13.3% of intensity
6.58 nm,
7.8% intensity
0.015% wt.
99.1% by weight
0.9% wt.
Two key weaknesses of DLS
1. Low resolution
two species are not resolved as separate peaks
unless their radii differ ~2-fold (~8-fold in mass)
consequently DLS is generally not useful to detect
or quantify small oligomers (dimer-octamer)
2. Poor quantitation of weight fractions
Usually at best the reproducibility of weight
fractions is only +/- a factor of 2
There is no universally-accepted standard
algorithm to calculate weight fractions; different
methods can give quite divergent results
Here is an example for a small peptide that
forms visible thread-like particles
7.9% intensity,
99.998% by weight
92.1% intensity,
0.002% by weight
species in the ~20-400
nm size range are often
precursors or nuclei for
formation of visible
particulates
In our hands DLS has been the most effective
tool for detecting precursors of visible particulates
1. Useful for qualitative assessment of different
formulations, ‘good’ vs. ‘bad’ lots
2. Useful to track where in the manufacturing process
damage to the protein is occurring
in one case tracked to specific pump
in another case to viral filtration step
3. Useful to detect contaminant particles that can serve
as nuclei onto which protein aggregates
(heterogeneous nucleation)
silicones
glass particles from vials
vacuum pump oil from lyophilizers
Strengths of DLS
1. high sensitivity to large aggregates that may be
immunogenic and/or precursors to visible
particulates
2. covers an enormous range of sizes in one analysis
(range of mass > 109)
3. done at equilibrium; theoretically senses all forms of
aggregates
4. batch mode
no dilution
no change of solvent conditions
no loss of species to frit or column matrix

More Related Content

What's hot

Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...
Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...
Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...
KBI Biopharma
 
Focus on aggregation: types, causes, characterization, and impact
Focus on aggregation: types, causes, characterization, and impactFocus on aggregation: types, causes, characterization, and impact
Focus on aggregation: types, causes, characterization, and impact
KBI Biopharma
 
New Approaches to Investigating the Self-Association and Colloidal Stability ...
New Approaches to Investigating the Self-Association and Colloidal Stability ...New Approaches to Investigating the Self-Association and Colloidal Stability ...
New Approaches to Investigating the Self-Association and Colloidal Stability ...
KBI Biopharma
 
Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...
Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...
Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...
KBI Biopharma
 
Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...
Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...
Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...
KBI Biopharma
 
Group_W_HF_and_Gel_Presentation
Group_W_HF_and_Gel_PresentationGroup_W_HF_and_Gel_Presentation
Group_W_HF_and_Gel_PresentationRashid Alsuwaidi
 
Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...
Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...
Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...
KBI Biopharma
 
Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...
Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...
Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...
KBI Biopharma
 
Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...
Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...
Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...
PerkinElmer, Inc.
 
Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...
Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...
Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...
IJERA Editor
 
Use of a Spectroscopic Sensor to Monitor DSD in emulsions using NN
Use of a Spectroscopic Sensor to Monitor DSD in emulsions using NNUse of a Spectroscopic Sensor to Monitor DSD in emulsions using NN
Use of a Spectroscopic Sensor to Monitor DSD in emulsions using NNCristhiane Assenhaimer Takahashi
 
Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...
Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...
Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...
European Sustainable Phosphorus Platform
 
Characterization of Supramolecular Polymers
Characterization of Supramolecular PolymersCharacterization of Supramolecular Polymers
Characterization of Supramolecular Polymers
Zohaib HUSSAIN
 
Analytical Ultracentrifugation 06
Analytical Ultracentrifugation 06Analytical Ultracentrifugation 06
Analytical Ultracentrifugation 06
Christiane Riedinger
 
Technical Engineering Memorandum_2015
Technical Engineering Memorandum_2015Technical Engineering Memorandum_2015
Technical Engineering Memorandum_2015Jordan Lopez
 
Lead isotope determinations by mass spectrometry and its application by isoto...
Lead isotope determinations by mass spectrometry and its application by isoto...Lead isotope determinations by mass spectrometry and its application by isoto...
Lead isotope determinations by mass spectrometry and its application by isoto...
Alexander Decker
 
Pages from IEEE_SENSORS_2014_PROCEEDINGS
Pages from IEEE_SENSORS_2014_PROCEEDINGSPages from IEEE_SENSORS_2014_PROCEEDINGS
Pages from IEEE_SENSORS_2014_PROCEEDINGSAlpha Mansaray
 
Lab 2 the spectrometer &; beer`s law
Lab 2 the spectrometer &; beer`s lawLab 2 the spectrometer &; beer`s law
Lab 2 the spectrometer &; beer`s law
Anas Maghayreh
 

What's hot (20)

Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...
Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...
Analysis of Aggregation, Stability, and Lot Comparability by Sedimentation Ve...
 
Focus on aggregation: types, causes, characterization, and impact
Focus on aggregation: types, causes, characterization, and impactFocus on aggregation: types, causes, characterization, and impact
Focus on aggregation: types, causes, characterization, and impact
 
New Approaches to Investigating the Self-Association and Colloidal Stability ...
New Approaches to Investigating the Self-Association and Colloidal Stability ...New Approaches to Investigating the Self-Association and Colloidal Stability ...
New Approaches to Investigating the Self-Association and Colloidal Stability ...
 
Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...
Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...
Reversible Association of a Monoclonal Antibody Studied by Concentration-Grad...
 
Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...
Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...
Aggregation Analysis of Therapeutic Proteins, Part 2: Analytical Ultracentrif...
 
Group_W_HF_and_Gel_Presentation
Group_W_HF_and_Gel_PresentationGroup_W_HF_and_Gel_Presentation
Group_W_HF_and_Gel_Presentation
 
Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...
Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...
Aggregation Analysis of Therapeutic Proteins, Part 1: General Aspects and Tec...
 
Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...
Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...
Aggregation Analysis of Therapeutic Proteins, Part 3: Principles and Optimiza...
 
Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...
Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...
Benefits of NexION 300D ICP-MS reaction mode in removing the Gd interference ...
 
Phys revb.72.184428
Phys revb.72.184428Phys revb.72.184428
Phys revb.72.184428
 
C5OB00465A (1)
C5OB00465A (1)C5OB00465A (1)
C5OB00465A (1)
 
Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...
Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...
Monitoring of the Sulfur and Nano Silver in Water by Method of Laser Spectros...
 
Use of a Spectroscopic Sensor to Monitor DSD in emulsions using NN
Use of a Spectroscopic Sensor to Monitor DSD in emulsions using NNUse of a Spectroscopic Sensor to Monitor DSD in emulsions using NN
Use of a Spectroscopic Sensor to Monitor DSD in emulsions using NN
 
Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...
Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...
Kai Bester - Aarhus University, Denmark - Removal of pharmaceuticals in diffe...
 
Characterization of Supramolecular Polymers
Characterization of Supramolecular PolymersCharacterization of Supramolecular Polymers
Characterization of Supramolecular Polymers
 
Analytical Ultracentrifugation 06
Analytical Ultracentrifugation 06Analytical Ultracentrifugation 06
Analytical Ultracentrifugation 06
 
Technical Engineering Memorandum_2015
Technical Engineering Memorandum_2015Technical Engineering Memorandum_2015
Technical Engineering Memorandum_2015
 
Lead isotope determinations by mass spectrometry and its application by isoto...
Lead isotope determinations by mass spectrometry and its application by isoto...Lead isotope determinations by mass spectrometry and its application by isoto...
Lead isotope determinations by mass spectrometry and its application by isoto...
 
Pages from IEEE_SENSORS_2014_PROCEEDINGS
Pages from IEEE_SENSORS_2014_PROCEEDINGSPages from IEEE_SENSORS_2014_PROCEEDINGS
Pages from IEEE_SENSORS_2014_PROCEEDINGS
 
Lab 2 the spectrometer &; beer`s law
Lab 2 the spectrometer &; beer`s lawLab 2 the spectrometer &; beer`s law
Lab 2 the spectrometer &; beer`s law
 

Similar to Analyzing Aggregates by Sedimentation Velocity and Light Scattering

Dls presentation edited
Dls presentation editedDls presentation edited
Dls presentation edited
PRIYA KUMARI
 
Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...
Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...
Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...
KBI Biopharma
 
Lc ms
Lc msLc ms
Methodology of targeted mass spectrometry
Methodology of  targeted mass spectrometryMethodology of  targeted mass spectrometry
Methodology of targeted mass spectrometry
Moustafa Rezk
 
Micromeritics
MicromeriticsMicromeritics
Micromeritics
Amit M Gupta
 
X ray-crstallography
X ray-crstallographyX ray-crstallography
X ray-crstallography
Tayyaba Fayaz
 
Analytical centrifugation
Analytical centrifugationAnalytical centrifugation
Analytical centrifugation
Varshini3
 
Analytical Ultracentrifugation of protein.
Analytical Ultracentrifugation of protein.Analytical Ultracentrifugation of protein.
Analytical Ultracentrifugation of protein.
DiNa Amin
 
Is Any Measurement Method Optimal for All Aggregate Sizes and Types?
Is Any Measurement Method Optimal for All Aggregate Sizes and Types? Is Any Measurement Method Optimal for All Aggregate Sizes and Types?
Is Any Measurement Method Optimal for All Aggregate Sizes and Types?
KBI Biopharma
 
DLS dynamic light scattering
DLS dynamic light scatteringDLS dynamic light scattering
DLS dynamic light scattering
Amina Khan
 
Particle size analysis in food industry.pptx
Particle size analysis in food industry.pptxParticle size analysis in food industry.pptx
Particle size analysis in food industry.pptx
Monika Sharma
 
1. f a q particles size analyzing
1. f a q particles size analyzing1. f a q particles size analyzing
1. f a q particles size analyzing
Mario P J Saragi
 
Introduction to Biomedical Optics
Introduction to Biomedical OpticsIntroduction to Biomedical Optics
Introduction to Biomedical Optics
Jad Ayoub
 
Method development
Method developmentMethod development
Method development
Nirav Soni
 
Int.+Spectroscopy+&+UV.ppt
Int.+Spectroscopy+&+UV.pptInt.+Spectroscopy+&+UV.ppt
Int.+Spectroscopy+&+UV.ppt
TahsinAhmed32
 
Ultracenrifugation by kanchana sivabalan
Ultracenrifugation by kanchana sivabalanUltracenrifugation by kanchana sivabalan
Ultracenrifugation by kanchana sivabalan
kanchana Sivabalan
 
-Particle-Size-Analysis-pptx.pptx
-Particle-Size-Analysis-pptx.pptx-Particle-Size-Analysis-pptx.pptx
-Particle-Size-Analysis-pptx.pptx
prashantingole13
 
Application X-Ray crystallography in protein structure prediction.pptx
Application X-Ray crystallography in protein structure prediction.pptxApplication X-Ray crystallography in protein structure prediction.pptx
Application X-Ray crystallography in protein structure prediction.pptx
SIRAJUDDIN MOLLA
 

Similar to Analyzing Aggregates by Sedimentation Velocity and Light Scattering (20)

Dls presentation edited
Dls presentation editedDls presentation edited
Dls presentation edited
 
Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...
Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...
Limitations and Advantages in Assessing Adenovirus Homogeneity by Laser Light...
 
Lc ms
Lc msLc ms
Lc ms
 
Methodology of targeted mass spectrometry
Methodology of  targeted mass spectrometryMethodology of  targeted mass spectrometry
Methodology of targeted mass spectrometry
 
Home exam answers
Home exam answersHome exam answers
Home exam answers
 
Micromeritics
MicromeriticsMicromeritics
Micromeritics
 
X ray-crstallography
X ray-crstallographyX ray-crstallography
X ray-crstallography
 
Analytical centrifugation
Analytical centrifugationAnalytical centrifugation
Analytical centrifugation
 
Analytical Ultracentrifugation of protein.
Analytical Ultracentrifugation of protein.Analytical Ultracentrifugation of protein.
Analytical Ultracentrifugation of protein.
 
Is Any Measurement Method Optimal for All Aggregate Sizes and Types?
Is Any Measurement Method Optimal for All Aggregate Sizes and Types? Is Any Measurement Method Optimal for All Aggregate Sizes and Types?
Is Any Measurement Method Optimal for All Aggregate Sizes and Types?
 
DLS dynamic light scattering
DLS dynamic light scatteringDLS dynamic light scattering
DLS dynamic light scattering
 
Particle size analysis in food industry.pptx
Particle size analysis in food industry.pptxParticle size analysis in food industry.pptx
Particle size analysis in food industry.pptx
 
1. f a q particles size analyzing
1. f a q particles size analyzing1. f a q particles size analyzing
1. f a q particles size analyzing
 
Introduction to Biomedical Optics
Introduction to Biomedical OpticsIntroduction to Biomedical Optics
Introduction to Biomedical Optics
 
Micellar aggregation number
Micellar aggregation numberMicellar aggregation number
Micellar aggregation number
 
Method development
Method developmentMethod development
Method development
 
Int.+Spectroscopy+&+UV.ppt
Int.+Spectroscopy+&+UV.pptInt.+Spectroscopy+&+UV.ppt
Int.+Spectroscopy+&+UV.ppt
 
Ultracenrifugation by kanchana sivabalan
Ultracenrifugation by kanchana sivabalanUltracenrifugation by kanchana sivabalan
Ultracenrifugation by kanchana sivabalan
 
-Particle-Size-Analysis-pptx.pptx
-Particle-Size-Analysis-pptx.pptx-Particle-Size-Analysis-pptx.pptx
-Particle-Size-Analysis-pptx.pptx
 
Application X-Ray crystallography in protein structure prediction.pptx
Application X-Ray crystallography in protein structure prediction.pptxApplication X-Ray crystallography in protein structure prediction.pptx
Application X-Ray crystallography in protein structure prediction.pptx
 

More from KBI Biopharma

Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...
KBI Biopharma
 
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
KBI Biopharma
 
High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...
KBI Biopharma
 
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...
KBI Biopharma
 
Application and Adaptation of Platform and Alternative Purification Steps to ...
Application and Adaptation of Platform and Alternative Purification Steps to ...Application and Adaptation of Platform and Alternative Purification Steps to ...
Application and Adaptation of Platform and Alternative Purification Steps to ...
KBI Biopharma
 
Primary Recovery & Harvest Processes for non-mAb Recombinant Proteins
Primary Recovery & Harvest Processes for non-mAb Recombinant ProteinsPrimary Recovery & Harvest Processes for non-mAb Recombinant Proteins
Primary Recovery & Harvest Processes for non-mAb Recombinant Proteins
KBI Biopharma
 
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
KBI Biopharma
 
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...
KBI Biopharma
 
Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...
Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...
Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...
KBI Biopharma
 
Host Cell Protein Analysis by Mass Spectrometry | KBI Biopharma
Host Cell Protein Analysis by Mass Spectrometry | KBI BiopharmaHost Cell Protein Analysis by Mass Spectrometry | KBI Biopharma
Host Cell Protein Analysis by Mass Spectrometry | KBI Biopharma
KBI Biopharma
 
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
KBI Biopharma
 
Octet Potency Assay: Development, Qualification and Validation Strategies
Octet Potency Assay: Development, Qualification and Validation StrategiesOctet Potency Assay: Development, Qualification and Validation Strategies
Octet Potency Assay: Development, Qualification and Validation Strategies
KBI Biopharma
 
Fine-tuning your purification process: Using mechanistic modeling of chromato...
Fine-tuning your purification process: Using mechanistic modeling of chromato...Fine-tuning your purification process: Using mechanistic modeling of chromato...
Fine-tuning your purification process: Using mechanistic modeling of chromato...
KBI Biopharma
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
KBI Biopharma
 
Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...
Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...
Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...
KBI Biopharma
 
Effects of Additives on Reversibility of Thermal Unfolding
Effects of Additives on Reversibility of Thermal UnfoldingEffects of Additives on Reversibility of Thermal Unfolding
Effects of Additives on Reversibility of Thermal Unfolding
KBI Biopharma
 
Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...
Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...
Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...
KBI Biopharma
 
Characterizing the aggregation and conformation of protein therapeutics
Characterizing the aggregation and conformation of protein therapeuticsCharacterizing the aggregation and conformation of protein therapeutics
Characterizing the aggregation and conformation of protein therapeutics
KBI Biopharma
 
Some Unusual Aggregation Phenomena in Recombinant Proteins
Some Unusual Aggregation Phenomena in Recombinant ProteinsSome Unusual Aggregation Phenomena in Recombinant Proteins
Some Unusual Aggregation Phenomena in Recombinant Proteins
KBI Biopharma
 
Highly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturingHighly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturing
KBI Biopharma
 

More from KBI Biopharma (20)

Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...
 
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
 
High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...
 
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...
Debottlenecking Manufacturing Capacity Using High Seed Density Production Pro...
 
Application and Adaptation of Platform and Alternative Purification Steps to ...
Application and Adaptation of Platform and Alternative Purification Steps to ...Application and Adaptation of Platform and Alternative Purification Steps to ...
Application and Adaptation of Platform and Alternative Purification Steps to ...
 
Primary Recovery & Harvest Processes for non-mAb Recombinant Proteins
Primary Recovery & Harvest Processes for non-mAb Recombinant ProteinsPrimary Recovery & Harvest Processes for non-mAb Recombinant Proteins
Primary Recovery & Harvest Processes for non-mAb Recombinant Proteins
 
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
 
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...
Speed to GMP: Moving from Rapid Process Development to High Throughput Tech T...
 
Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...
Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...
Implementation of End-to-End Disposable Single Use Systems for Rapid Fermenta...
 
Host Cell Protein Analysis by Mass Spectrometry | KBI Biopharma
Host Cell Protein Analysis by Mass Spectrometry | KBI BiopharmaHost Cell Protein Analysis by Mass Spectrometry | KBI Biopharma
Host Cell Protein Analysis by Mass Spectrometry | KBI Biopharma
 
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
 
Octet Potency Assay: Development, Qualification and Validation Strategies
Octet Potency Assay: Development, Qualification and Validation StrategiesOctet Potency Assay: Development, Qualification and Validation Strategies
Octet Potency Assay: Development, Qualification and Validation Strategies
 
Fine-tuning your purification process: Using mechanistic modeling of chromato...
Fine-tuning your purification process: Using mechanistic modeling of chromato...Fine-tuning your purification process: Using mechanistic modeling of chromato...
Fine-tuning your purification process: Using mechanistic modeling of chromato...
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
 
Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...
Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...
Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and ...
 
Effects of Additives on Reversibility of Thermal Unfolding
Effects of Additives on Reversibility of Thermal UnfoldingEffects of Additives on Reversibility of Thermal Unfolding
Effects of Additives on Reversibility of Thermal Unfolding
 
Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...
Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...
Online Size-Exclusion High-Performance Liquid Chromatography Light Scattering...
 
Characterizing the aggregation and conformation of protein therapeutics
Characterizing the aggregation and conformation of protein therapeuticsCharacterizing the aggregation and conformation of protein therapeutics
Characterizing the aggregation and conformation of protein therapeutics
 
Some Unusual Aggregation Phenomena in Recombinant Proteins
Some Unusual Aggregation Phenomena in Recombinant ProteinsSome Unusual Aggregation Phenomena in Recombinant Proteins
Some Unusual Aggregation Phenomena in Recombinant Proteins
 
Highly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturingHighly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturing
 

Recently uploaded

Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
SwastikAyurveda
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
planning for change nursing Management ppt
planning for change nursing Management pptplanning for change nursing Management ppt
planning for change nursing Management ppt
Thangamjayarani
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 

Recently uploaded (20)

Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
planning for change nursing Management ppt
planning for change nursing Management pptplanning for change nursing Management ppt
planning for change nursing Management ppt
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 

Analyzing Aggregates by Sedimentation Velocity and Light Scattering

  • 1. Analyzing Aggregates by Sedimentation Velocity and Light Scattering John Philo Director of Biophysical Chemistry © copyright 2006, Alliance Protein Laboratories, Inc. Images or text may not be reproduced without permission.
  • 2. Outline Quickly review some basic facts about aggregate sizes and types Basic principles and application examples for 3 methods 1. sedimentation velocity 2. classical light scattering used with SEC 3. batch-mode dynamic light scattering
  • 3. The word “aggregate” covers a wide spectrum of types and sizes of associated states 1. rapidly-reversible non-covalent small oligomers (dimer, trimer, tetramer…) 2. irreversible non-covalent oligomers 3. covalent oligomers (e.g. disulfides) 4. “large” aggregates (> 10-mer) could be reversible if non-covalent 5. “very large” aggregates (diameter ~50 nm to 3 μm) could be reversible if non-covalent 6. visible particulates probably irreversible
  • 4. Aggregates have a spectrum of lifetimes rates of non-covalent association and dissociation (half- times) can vary from milliseconds to days metastable oligomers with dissociation rates of hours to days occur fairly frequently for an antibody example see J.M.R. Moore et al. (1999) Biochemistry 38: 13960-13967 see also Philo, J.S. (2006) AAPS Journal, in press many common analytical methods will detect only the longer-lived species it may take hours to days for a protein to re-equilibrate its association after a change in concentration, solvent conditions or temperature
  • 5. Our analytical challenge 1. Any protein sample may contain aggregates with a wide range of sizes, types, and lifetimes 2. Any one analysis method may not detect all the aggregate sizes or types that are present 3. The measurement itself may perturb the aggregate distribution that was initially present dilution may dissociate reversible aggregates change of solvent conditions may dissociate or increase aggregates adsorption or filtration effects may remove aggregates
  • 7. The fundamentals of sedimentation velocity 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 Radius (cm) -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 Absorbance 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 Radius (cm) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 Absorbance centrifugal force diffusion ← meniscus The sedimentation coefficient is determined from the boundary motion over time. It depends on both molecular weight and molecular shape. cell base → friction ←regionofsolute depletion boundary
  • 8. High resolution analysis of a highly stressed antibody sample resolves 6 aggregate peaks plus 2 fragments 0 2 4 6 8 10 12 14 16 18 20 22 24 0.0 0.2 0.4 0.6 0.8 1.0 heptamer,0.1% hexamer,0.4% pentamer1.4% tetramer5.3% trimer14.6% dimer30.6% main peak (monomer), 45.5% ?HLhalfmolecule,0.8% ?freelightchain,1.4% c(s),normalized(totalarea=1) sedimentation coefficient (Svedbergs)
  • 9. The peril: c(s) distributions are also often misunderstood 1. the effective resolution goes down as the fraction of minor peaks goes down 2. the resolution you can achieve for a 150 kDa antibody is much greater than for a 20 kDa cytokine 3. in general it is not possible to uniquely assign a stoichiometry to each aggregate peak 4. the nature of the noise (variability) is very different than in chromatography 5. for reversibly associating proteins the peaks probably do not represent individual molecular species
  • 10. This interferon-β sample is 13.7% non-covalent aggregate; by the standard SEC method it would be pure monomer 0 2 4 6 8 10 0 1 2 3 4 5 6 7 0 2 4 6 8 10 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 IFN-β in 5 mM glycine, pH 3, 86.3% main peak c(s) sedimentation coefficient (Svedbergs)
  • 11. 0 1 2 3 0.0 0.5 1.0 1.5 0 8 16 24 32 40 0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 no salt c(s) +50 mM NaCl c(s) +150 mM NaCl c(s) sedimentation coefficient (Svedbergs) 0 2 4 6 8 10 0.00 0.05 0.10 0.15 20X expanded 0 2 4 6 8 10 0.00 0.05 0.10 0.15 20X expanded Adding NaCl to interferon-β formulations leads to a broad distribution of non-covalent aggregates out to ~100-mers
  • 12. Strengths of sedimentation velocity 1. high resolution (often better than SEC) 2. covers very large range of masses in a single experiment (much larger than SEC) 3. detects both covalent and non-covalent aggregates 4. generally can be done directly in formulation buffers Tween and high levels of sugars do cause some interference 5. little dilution of sample (~25%) 6. absolute method; requires no molecular standards 7. strong theoretical background; “first principles” method
  • 13. Weaknesses of sedimentation velocity 1. low throughput (3-7 samples/day) 2. equipment and data analysis not automated like HPLC; labor intensive 3. expensive equipment (~250-300 K$) 4. requires substantial training 5. never been validated for lot release Sedimentation velocity can not replace SEC, but it is an excellent tool to test whether SEC is missing important features. It can also serve as a “gold standard” to help improve SEC methods.
  • 14. Multi-angle classical laser light scattering used on-line with SEC (SEC-MALLS)
  • 15. Typical setup for size-exclusion chromatography with on-line light scattering detection light scattering detector absorbance detector refractive index detector size-exclusion column injectorpumpsolvent
  • 16. Getting molecular mass from static light scattering: the basic idea the light scattering signal is proportional to the product c × M we measure c simultaneously with a UV or RI detector then the ratio of the scattering to concentration signals will be proportional to M masses obtained this way are absolute, and independent of conformation and elution position
  • 17. Demonstrating that scattering is independent of elution position and molecular conformation: the ratio of LS to RI signals is the same whether the protein is folded or unfolded 18 20 22 24 26 28 signal(arbitraryunits) LS RI LS RI Native RNase Unfolded (reduced & carboxymethlyated) RNase Retention Time (min)
  • 18. An example for an Fc-fusion protein: the aggregate signals are much stronger in 90° scattering than in the UV chromatogram scattering intensity RI elution volume (ml) 5.0 6.0 7.0 8.0 9.0 10.0 11.0 relativescale 0.0 0.2 0.4 0.6 0.8 1.0
  • 19. “Oligomer hunting”: display the absolute molecular weight from LS in units of monomers 6 7 8 9 10 11 0 1 2 3 4 5 6 7 8 9 10 massratiorelativetomainpeak elution volum e (m l)
  • 20. This antibody sample has traces of dimer and trimer 12 13 14 15 16 17 18 Elution Volume (ml) 0.0 1.0 2.0 3.0 4.0 5.0 relativemassfromLS/UV relative mass (LS/UV) UV (arb units)
  • 21. A different lot contains more higher oligomers, and they are so sticky that even dimer is no longer resolved 11 12 13 14 15 16 17 18 Elution Volume (ml) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 relativemassfromLS/UV relative mass (LS/UV) UV (arb units)
  • 22. volume (ml) 5.0 6.0 7.0 8.0 9.0 10.0 relativescale 0.0 0.2 0.4 0.6 0.8 1.0 This highly stressed sample of a VaxGen test antigen showed high levels of an SEC peak eluting near the position expected for a dimer monomer dimer? large aggregates
  • 23. However SEC-MALLS immediately shows that alleged aggregate is actually an altered form of monomer! molar mass vs. volume volume 5.0 6.0 7.0 8.0 9.0 10.0 molarmass(g/mol) 5 1.0x10 6 1.0x10 7 1.0x10
  • 24. Strengths of SEC + classical LS 1. absolute molecular mass, independent of conformation or elution position 2. gives us at least an average mass for the “aggregate” fraction near the exclusion limit 3. helps tell us whether our chromatography is really working properly 4. high throughput, low cost (comparable to the HPLC it is used with), fairly easy 5. absolute method; requires no molecular standards 6. strong theoretical background; “first principles” method
  • 25. Weaknesses of SEC + classical LS 1. it inherits all the problems of SEC (change in aggregate distribution from dilution, change in buffer, adsorption/filtration, etc.) 2. while it is very sensitive to high MW aggregates, quantitation of % by weight still relies on the concentration detector (RI or UV) 3. particles shed from columns may obscure the elution region near the column’s exclusion limit 4. good signal/noise may require larger injection amounts than are normally used in standard SEC
  • 26. Batch-mode dynamic light scattering (DLS) also known as quasi-elastic light scattering (QELS) or photon correlation spectroscopy (PCS)
  • 27. One particularly vexing type of aggregation is “snow” (a.k.a. “white amorphous material” [WAM] or “floaters”) • may only appear after many months • often a nucleation-controlled reaction • often ≤ 0.01% of total protein
  • 28. ⇒ When this happens our valuable therapeutic protein can only be used for… Dynamic scattering is one of the few tools that may be able to detect the precursors that eventually form ‘snow’
  • 29. Dynamic light scattering: the basic idea 1. In dynamic scattering we measure the fluctuations in scattering intensity (~100 ns to 30 ms) 2. The time scale of those fluctuations depends on the diffusion coefficient of the macromolecule, which in turn depends on its size 3. As in classical LS, the scattering intensity is proportional to M, so the sensitivity to very large aggregates is very high
  • 30. Typically the data are transformed into a distribution of hydrodynamic radius; this distribution shows 3 peaks 2.16 nm, 79.0% of intensity 92.3 nm, 13.3% of intensity 6.58 nm, 7.8% intensity 0.015% wt. 99.1% by weight 0.9% wt.
  • 31. Two key weaknesses of DLS 1. Low resolution two species are not resolved as separate peaks unless their radii differ ~2-fold (~8-fold in mass) consequently DLS is generally not useful to detect or quantify small oligomers (dimer-octamer) 2. Poor quantitation of weight fractions Usually at best the reproducibility of weight fractions is only +/- a factor of 2 There is no universally-accepted standard algorithm to calculate weight fractions; different methods can give quite divergent results
  • 32. Here is an example for a small peptide that forms visible thread-like particles 7.9% intensity, 99.998% by weight 92.1% intensity, 0.002% by weight species in the ~20-400 nm size range are often precursors or nuclei for formation of visible particulates
  • 33. In our hands DLS has been the most effective tool for detecting precursors of visible particulates 1. Useful for qualitative assessment of different formulations, ‘good’ vs. ‘bad’ lots 2. Useful to track where in the manufacturing process damage to the protein is occurring in one case tracked to specific pump in another case to viral filtration step 3. Useful to detect contaminant particles that can serve as nuclei onto which protein aggregates (heterogeneous nucleation) silicones glass particles from vials vacuum pump oil from lyophilizers
  • 34. Strengths of DLS 1. high sensitivity to large aggregates that may be immunogenic and/or precursors to visible particulates 2. covers an enormous range of sizes in one analysis (range of mass > 109) 3. done at equilibrium; theoretically senses all forms of aggregates 4. batch mode no dilution no change of solvent conditions no loss of species to frit or column matrix